![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Novartis |
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00170781 |
This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout. This is a multi-center, double-blind, randomized, parallel group study comparing a single daily dose of 400 mg lumiracoxib with the established dose of indomethacin 50 mg taken three times a day in terms of efficacy
Condition | Intervention | Phase |
Acute Gouty Arthritis |
Drug: Lumiracoxib |
Phase IV |
MedlinePlus related topics: | Gout |
Drug Information available for: | Lumiracoxib Indomethacin |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 1-Week, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel Trial Comparing Lumiracoxib (400 mg Once Daily) in Patients With Acute Flares of Gout, Using Indomethacin (50 mg Three Times a Day) |
Estimated Enrollment: | 234 |
Study Start Date: | June 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Germany | |||||
Novartis | |||||
Nuernberg, Germany | |||||
Switzerland, CH | |||||
For Site Information, contact Novartis Pharma AG | |||||
Basel, CH, Switzerland, 4002 |
Novartis |
Study Chair: | Novartis Pharma AG | Sponsor GmbH |
Study ID Numbers: | CCOX189A2426 |
First Received: | September 9, 2005 |
Last Updated: | November 29, 2006 |
ClinicalTrials.gov Identifier: | NCT00170781 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
|
|
|
|
![]() |